End of another dramatic week, and the Short Only Strategy is now up 20%. Thanks of course to some huge downmoves since last week, especially on HDIL.
Now I’ll maintain a trailing stop loss of about 10% on each position, just to ensure things are ok. I might choose to add more later this week, for the December expiry.
Natco Pharma, a leader in APIs and niche generics, faces growth challenges post-Revlimid exclusivity in FY26, with semaglutide offering long-term ...
TARIL is one of the leading transformer manufacturers in India, and with the country’s growing power demand, the company is well-positioned to play a crucial ...
Jubilant Pharmova is a multifaceted pharma player, standing amidst a blend of growth and transformation. While some its segments are showing robust growth ...